Last reviewed · How we verify
Permethrin Foam 4%
At a glance
| Generic name | Permethrin Foam 4% |
|---|---|
| Also known as | PF-045 |
| Sponsor | Mylan Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies (PHASE2)
- Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Permethrin Foam 4% CI brief — competitive landscape report
- Permethrin Foam 4% updates RSS · CI watch RSS
- Mylan Inc. portfolio CI